{"symbol":"LLY","fiscalQuarter":"Q3-2021","reportDate":"2021-10-26","reportTime":"BMO","status":"reported","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q3-2021","postBrief":{"headline":"Eli Lilly Misses on EPS, Stock Down N/A%","keyNumbers":[{"metric":"EPS","actual":"$1.94","expected":"N/A","surprise":"-1.77%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["Management highlighted ongoing challenges in the market.","They emphasized a focus on long-term growth despite current pressures."],"summary":"Management expressed concerns about market conditions affecting performance. They remain focused on strategic initiatives to drive future growth."},"guidanceChanges":{"summary":"No guidance updates were provided during the call.","changes":[]},"whatItMeans":"Eli Lilly's earnings report shows a slight miss on EPS, indicating some challenges the company is facing. Without revenue figures available, it's hard to assess the full impact. The lack of guidance may leave investors uncertain about the company's future direction. The stock reaction is currently not available, which adds to the ambiguity surrounding the report.","metaDescription":"Eli Lilly (LLY) Q3 2021 earnings: EPS missed expectations. Stock reaction not available. Full breakdown."}}